Aimee is a physician-scientist and her research focuses on improving cellular therapies, such as NK cells, to treat multiple myeloma. To eventually cure myeloma, we need to develop a better understanding of the how the tumor microenvironment impacts treatment response to cellular therapies. Her work is testing various mechanisms to target suppressive cells and improve NK cell function. She currently has a clinical trial of an off-the-shelf NK cell product that has been engineered to express a chimeric antigen receptor (CAR) against B cell maturation antigen (BCMA) on myeloma cells that is open for relapsed myeloma patients. Other work in her lab is using a tri-specific killer engager (TriKE) that targets B7-H3, a cancer antigen present on both myeloma and myeloid derived suppressor cells (MDSC). MDSC play a role in the progression of myeloma and contribute to the development of bone lesions. Her personal goal is to provide novel treatments for her myeloma patients while continuing to work toward the goal of ultimately curing this cancer.